dr. philip bonomi: gefitinib and later generations of egfr inhibitors
Published 11 years ago • 479 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
2:30
gracecastuc088_lung_dr. bonomi on lung cancer targeted therapies
-
2:12
gracecastuc-078_lung_dr. bonomi on most promising new targeted agents and molecular pathways for lc
-
1:18
which advanced nsclc patients recommend repeat biopsies for molecular testing
-
2:22
gracecastuc-032_lung_dr. bonomi - maint. therapy after first line chemo a mandate, option, neither?
-
3:32
gracecastuc102_kidney_dr. bonomi on targeted therapy toxicity chemotherapy
-
6:02
肺癌的分布和成因 - distribution and causes of lung cancer - 2022 program: mandarin lcvl
-
5:29
gut microbiota and ageing | simin nikbin meydani
-
6:16
"these scientists have figured out how to block the brakes of the immune system."
-
0:52
dr. phil bonomi: recommending a repeat biopsy with acquired resistance to a targeted therapy
-
1:20
gracecastuc116_lung_dr. bonomi on how to manage acquired resistance
-
4:45
amivantamab and mobocertinib: side effects and treatment timing - lung cancer
-
1:26
first line treatment of egfr mutation-positive nsclc
-
2:57
future directions of b-cell lymphoma treatment - blood cancer video library 2023
-
7:59
dacomitinib beats iressa as first line treatment for egfr mutation-positive nsclc
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
7:53
improved progression-free survival with iressa as adjuvant therapy
-
18:44
2020 ttf egfr breakout piotrowska part 2 - current options upon acquired resistance to osimertinib
-
29:24
gracecast-068_lung-cancer_sequist on acquired resistance to egfr
-
5:38
curable hpv negative head and neck cancer
-
11:23
2020 ttf egfr breakout piotrowska part 1 - current options upon acquired resistance to osimertinib
-
1:53
lf fellow: cordelia imig investigates miscommunication between brain and gut